Skip Navigation
Skip to contents

Journal of Microbiology : Journal of Microbiology

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "virus-like particles"
Filter
Filter
Article category
Keywords
Publication year
Journal Article
IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation
Min-Hye Park , Ji Won You , Hyoung Jin Kim , Hong-Jin Kim
J. Microbiol. 2019;57(9):821-827.   Published online August 27, 2019
DOI: https://doi.org/10.1007/s12275-019-9308-z
  • 52 View
  • 0 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract
Most commercialized virus-like particle (VLP) vaccines use aluminum salt as adjuvant, even though VLPs provoke adequate antibody responses without adjuvant. We do not have detailed knowledge of how adjuvant affects the profile of anti- VLP antibodies. Meanwhile, there is evidence that differences between vaccination protocols influence the glycosylation of antibodies, which may alter their effector functions. In the present study a murine model was used to investigate the effects of dosing schedule and adjuvant on the antibody profiles and glycosylation levels of antigen-specific antibody responses to human papillomavirus type 16 L1 (HPV16 L1) VLPs. Mice received subcutaneously 2,000 ng of antigen divided into 4 or 7 doses. The HPV16 L1 VLPs elicited > 4 log10 anti-HPV16 L1 IgG titers without adjuvant, and aluminum hydroxide as adjuvant increased IgG titers 1.3- to 4-fold and reduced the anti-HPV16 L1 IgG2a / anti-HPV16 L1 IgG1 ratio value (use of aluminum hydroxide reduced the ratio of the IgG2a). Immunization with HPV16 L1 VLPs in combination with Freund’s adjuvant enhanced IgG titers 5- to 12- fold. Seven-dose immunization markedly increased anti- HPV16 L1 IgM titers compared to four-dose immunization, as well as increasing the proportion of glycosylated antibodies. Our results suggest that antibody glycosylation can be controlled immunologically, and IgG and IgM profiles and glycosylation profiles of the vaccine-induced antibodies can be used as indicators reflecting the vaccine characteristics. These
results
indicate that the HPV16 L1 VLP dosing schedule can affect the quality of antigen-specific antibody responses. We suggest that dosing schedules should be noted in vaccination protocols for VLP-based vaccines.

Citations

Citations to this article as recorded by  
  • Human papillomavirus vaccines: organisation and experience of preclinical studies
    A. S. Korovkin, T. N. Nikitina, T. Yu. Kozlova, D. V. Gorenkov, A. R. Volgin
    Biological Products. Prevention, Diagnosis, Treatment.2024; 24(3): 243.     CrossRef
  • Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice
    Sima Sazegari, Malihe Akbarzadeh Niaki, Alireza Afsharifar, Ali Niazi, Abdollah Derakhshandeh, Maryam Moradi Vahdat, Farshad Hemmati, Mohammad Hadi Eskandari
    Microbial Cell Factories.2023;[Epub]     CrossRef
  • Anti-JMH alloantibody in inherited JMH-negative patients leads to immunogenic destruction of JMH-positive RBCs
    Zhaohu Yuan, Yaming Wei, Xiaojie Chen, Shufei He, Kui Cai, Minglu Zhong, Huiying Huang, Xinxin Tong, Zhen Liu, Xuexin Yang
    Clinical and Experimental Immunology.2021; 205(2): 182.     CrossRef
  • Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women
    Elham Hassen, Devendra Bansal, Randa Ghdira, Anouar Chaieb, Hedi Khairi, Abdelfattah Zakhama, Sami Remadi, Johan Hoebeke, Ali A. Sultan, Lotfi Chouchane
    Journal of Translational Medicine.2020;[Epub]     CrossRef
Review
REVIEW] Exploiting virus-like particles as innovative vaccines against emerging viral infections
Hotcherl Jeong , Baik Lin Seong
J. Microbiol. 2017;55(3):220-230.   Published online February 28, 2017
DOI: https://doi.org/10.1007/s12275-017-7058-3
  • 47 View
  • 0 Download
  • 52 Crossref
AbstractAbstract
Emerging viruses pose a major threat to humans and livestock with global public health and economic burdens. Vaccination remains an effective tool to reduce this threat, and yet, the conventional cell culture often fails to produce sufficient vaccine dose. As an alternative to cell-culture based vaccine, virus-like particles (VLPs) are considered as a highpriority vaccine strategy against emerging viruses. VLPs represent highly ordered repetitive structures via macromolecular assemblies of viral proteins. The particulate nature allows efficient uptake into antigen presenting cells stimulating both innate and adaptive immune responses towards enhanced vaccine efficacy. Increasing research activity and translation opportunity necessitate the advances in the design of VLPs and new bioprocessing modalities for efficient and cost-effective production. Herein, we describe major achievements and challenges in this endeavor, with respect to designing strategies to harnessing the immunogenic potential, production platforms, downstream processes, and some exemplary
case
s in developing VLP-based vaccines.

Citations

Citations to this article as recorded by  
  • Harnessing Pentameric Scaffold of Cholera Toxin B (CTB) for Design of Subvirion Recombinant Dengue Virus Vaccine
    Jemin Sung, Yucheol Cheong, Young-Seok Kim, Jina Ahn, Myung Hyun Sohn, Sanguine Byun, Baik-Lin Seong
    Vaccines.2024; 12(1): 92.     CrossRef
  • Global progress in clinical research on human respiratory syncytial virus vaccines
    Ruofan Peng, Chenghao Chen, Qian Chen, Yuwen Zhang, Renjin Huang, Yanjun Zhang, Jianhua Li
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Virus-like particles in poultry disease: an approach to effective and safe vaccination
    Abdullahi Abdullahi Raji, Paniz Zarghami Dastjerdi, Abdul Rahman Omar
    Frontiers in Veterinary Science.2024;[Epub]     CrossRef
  • Sf9 Cell Metabolism Throughout the Recombinant Baculovirus and Rabies Virus-Like Particles Production in Two Culture Systems
    Luis Giovani Oliveira Guardalini, Jaci Leme, Paulo Eduardo da Silva Cavalcante, Renata Gois de Mello, Thaissa Consoni Bernardino, Simone Gonçalves Silva Jared, Marta Maria Antoniazzi, Renato Mancini Astray, Aldo Tonso, Eutimio Gustavo Fernández Núñez, Sor
    Molecular Biotechnology.2024; 66(2): 354.     CrossRef
  • Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview
    Ruth Henríquez, Isabel Muñoz-Barroso
    Heliyon.2024; 10(15): e34927.     CrossRef
  • Design and Application of Biosafe Coronavirus Engineering Systems without Virulence
    Guoqiang Wu, Qiaoyu Li, Junbiao Dai, Guobin Mao, Yingxin Ma
    Viruses.2024; 16(5): 659.     CrossRef
  • Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers Matter
    Sara Molenda, Agata Sikorska, Anna Florczak, Patryk Lorenc, Hanna Dams-Kozlowska
    Cancers.2023; 15(23): 5647.     CrossRef
  • Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery
    Vartika Srivastava, Kripa N. Nand, Aijaz Ahmad, Ravinder Kumar
    Vaccines.2023; 11(2): 479.     CrossRef
  • Viral protein-based nanoparticles (part 2): Pharmaceutical applications
    Rocio Mellid-Carballal, Sara Gutierrez-Gutierrez, Carmen Rivas, Marcos Garcia-Fuentes
    European Journal of Pharmaceutical Sciences.2023; 189: 106558.     CrossRef
  • Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants
    Nicola Principi, Giovanni Autore, Serafina Perrone, Susanna Esposito
    Expert Opinion on Pharmacotherapy.2023; 24(6): 747.     CrossRef
  • Viral Nanoparticles‐Mediated Delivery of Therapeutic Cargo
    Saba Zanganeh, Mohammad Doroudian, Zohreh R. Nowzari, Pourya Nasirmoghadas, Javid Sadri Nahand, Shima Sepehrpour, Mohsen Moghoofei
    Advanced Therapeutics.2023;[Epub]     CrossRef
  • Emerging Trends and Future Challenges of Nanovaccine Delivery via Nasal Route
    Hitesh Kumar Dewangan, Akash Raghuvanshi, Kamal Shah
    Current Drug Targets.2023; 24(3): 261.     CrossRef
  • A Virus-like Particle-Based F4 Enterotoxigenic Escherichia coli Vaccine Is Inhibited by Maternally Derived Antibodies in Piglets but Generates Robust Responses in Sows
    Kara-Lee Aves, Priscila R. Guerra, Ana H. Fresno, Mauro M. S. Saraiva, Eric Cox, Poul J. Bækbo, Morten A. Nielsen, Adam F. Sander, John E. Olsen
    Pathogens.2023; 12(12): 1388.     CrossRef
  • Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application
    Lei Zhang, Wen Xu, Xi Ma, XiaoJing Sun, JinBo Fan, Yang Wang
    Biotechnology and Bioprocess Engineering.2023; 28(1): 1.     CrossRef
  • Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications
    Ernesto Garay, Diego Fontana, Lautaro Leschiutta, Ricardo Kratje, Claudio Prieto
    Applied Microbiology and Biotechnology.2022; 106(2): 579.     CrossRef
  • Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery
    Audrey Olshefsky, Christian Richardson, Suzie H. Pun, Neil P. King
    Bioconjugate Chemistry.2022; 33(11): 2018.     CrossRef
  • Can Virus-like Particles Be Used as Synergistic Agent in Pest Management?
    Caroline Deshayes, Anne-Sophie Gosselin-Grenet, Mylène Ogliastro, Bruno Lapied, Véronique Apaire-Marchais
    Viruses.2022; 14(5): 943.     CrossRef
  • Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
    Hasnat Tariq, Sannia Batool, Saaim Asif, Mohammad Ali, Bilal Haider Abbasi
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Development and characterization of monoclonal antibodies against red-spotted grouper nervous necrosis virus and their neutralizing potency in vitro
    Zhiqi Zhang, Jing Xing, Xiaoqian Tang, Xiuzhen Sheng, Heng Chi, Wenbin Zhan
    Aquaculture.2022; 560: 738562.     CrossRef
  • Sendai virus particles carrying target virus glycoproteins for antibody induction
    Hiroshi Ishii, Midori Nakamura-Hoshi, Tsugumine Shu, Tetsuro Matano
    Vaccine.2022; 40(16): 2420.     CrossRef
  • Emerging Frontiers in Vaccine Development: A Review of Changing Paradigm
    Ishan Ghosh, Mohit D. Gandhi
    Journal of Biosciences and Medicines.2022; 10(07): 123.     CrossRef
  • An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
    Alessio Facciolà, Giuseppa Visalli, Antonio Laganà, Angela Di Pietro
    Vaccines.2022; 10(5): 819.     CrossRef
  • RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform
    Beom Jeung Hwang, Yohan Jang, Soon Bin Kwon, Ji Eun Yu, Jongkwan Lim, Young Hoon Roh, Baik L. Seong
    Biomaterials.2021; 269: 120650.     CrossRef
  • Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery
    Kingshuk Dutta, Ritam Das, Jewel Medeiros, S. Thayumanavan
    Biochemistry.2021; 60(13): 966.     CrossRef
  • Engineering Tobacco Mosaic Virus and Its Virus‐Like‐Particles for Synthesis of Biotemplated Nanomaterials
    Kok Zhi Lee, Vindula Basnayake Pussepitiyalage, Yu‐Hsuan Lee, L. Sue Loesch‐Fries, Michael T. Harris, Shohreh Hemmati, Kevin V. Solomon
    Biotechnology Journal.2021;[Epub]     CrossRef
  • Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future
    Ester Calvo Fernández, Lucie Y. Zhu
    British Journal of Clinical Pharmacology.2021; 87(9): 3408.     CrossRef
  • Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
    Halle Lutz, Kristen D. Popowski, Phuong-Uyen C. Dinh, Ke Cheng
    Advanced NanoBiomed Research.2021;[Epub]     CrossRef
  • RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform
    Jongkwan Lim, Yucheol Cheong, Young-Seok Kim, Wonil Chae, Beom Jeung Hwang, Jinhee Lee, Yo Han Jang, Young Hoon Roh, Sang-Uk Seo, Baik L. Seong
    Nanomedicine: Nanotechnology, Biology and Medicine.2021; 37: 102438.     CrossRef
  • Nano-based approaches in the development of antiviral agents and vaccines
    Yang Li, Yushuo Xiao, Yuchen Chen, Kun Huang
    Life Sciences.2021; 265: 118761.     CrossRef
  • Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers
    Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini, Camellia Katalani, Abbas Hajizade, Andrew J. Easton, Gholamreza Ahmadian
    Journal of Nanobiotechnology.2021;[Epub]     CrossRef
  • VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases
    Aline Maria Vasconcelos Queiroz, Johny Wysllas de Freitas Oliveira, Cláudia Jassica Moreno, Diego M. A. Guérin, Marcelo Sousa Silva
    Vaccines.2021; 9(3): 220.     CrossRef
  • Nervous Necrosis Virus-like Particle (VLP) Vaccine Stimulates European Sea Bass Innate and Adaptive Immune Responses and Induces Long-Term Protection against Disease
    Sofie Barsøe, Kerstin Skovgaard, Dagoberto Sepúlveda, Ansgar Stratmann, Niccolò Vendramin, Niels Lorenzen
    Pathogens.2021; 10(11): 1477.     CrossRef
  • Long-Term Protection and Serologic Response of European Sea Bass Vaccinated with a Betanodavirus Virus-Like Particle Produced in Pichia pastoris
    Sofie Barsøe, Anna Toffan, Francesco Pascoli, Ansgar Stratmann, Tobia Pretto, Andrea Marsella, Mériem Er-Rafik, Niccolò Vendramin, Niels J. Olesen, Dagoberto Sepúlveda, Niels Lorenzen
    Vaccines.2021; 9(5): 447.     CrossRef
  • Expression, Purification, and Characterization of Bovine Leukemia Virus-Like Particles Produced in Drosophila S2 Cells
    Natalia Olivero-Deibe, Lorena Tomé-Poderti, Federico Carrión, Sergio Bianchi, Martín Fló, Daniel Prieto, Florencia Rammauro, Andrés Addiego, Natalia Ibañez, Madelón Portela, Rosario Duran, Mabel Berois, Otto Pritsch
    Frontiers in Virology.2021;[Epub]     CrossRef
  • Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines
    Acharya Balkrishna, Vedpriya Arya, Akansha Rohela, Ashwani Kumar, Rachna Verma, Dinesh Kumar, Eugenie Nepovimova, Kamil Kuca, Naveen Thakur, Nikesh Thakur, Pankaj Kumar
    Vaccines.2021; 9(10): 1129.     CrossRef
  • Baculovirus affinity removal in viral-based bioprocesses
    Mafalda G. Moleirinho, Rita P. Fernandes, Sofia B. Carvalho, Sandra Bezemer, Frank Detmers, Pim Hermans, Ricardo J.S. Silva, Paula M. Alves, Manuel J.T. Carrondo, Cristina Peixoto
    Separation and Purification Technology.2020; 241: 116693.     CrossRef
  • Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
    Naru Zhang, Chaoqun Li, Shibo Jiang, Lanying Du
    Vaccines.2020; 8(3): 481.     CrossRef
  • A Flow-Through Chromatographic Strategy for Hepatitis C Virus-Like Particles Purification
    Ricardo J. S. Silva, Mafalda G. Moleirinho, Ana S. Moreira, Alex Xenopoulos, Paula M. Alves, Manuel J. T. Carrondo, Cristina Peixoto
    Processes.2020; 8(1): 85.     CrossRef
  • Virus-like particle vaccine displaying Toxoplasma gondii apical membrane antigen 1 induces protection against T. gondii ME49 infection in mice
    Min-Ju Kim, Su-Hwa Lee, Hae-Ji Kang, Ki-Back Chu, Hyunwoo Park, Hui Jin, Eun-Kyung Moon, Sung Soo Kim, Fu-Shi Quan
    Microbial Pathogenesis.2020; 142: 104090.     CrossRef
  • Bacterial Production of Barley Stripe Mosaic Virus Biotemplates for Palladium Nanoparticle Growth
    Yu-Hsuan Lee, Kok Zhi Lee, Rachel G. Susler, Corren A. Scott, Longfei Wang, L. Sue Loesch-Fries, Michael T. Harris, Kevin V. Solomon
    ACS Applied Nano Materials.2020; 3(12): 12080.     CrossRef
  • Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
    Carlotta Biagi, Arianna Dondi, Sara Scarpini, Alessandro Rocca, Silvia Vandini, Giulia Poletti, Marcello Lanari
    Vaccines.2020; 8(4): 672.     CrossRef
  • Virus-like particle-display of the enterotoxigenic Escherichia coli heat-stable toxoid STh-A14T elicits neutralizing antibodies in mice
    Morten L. Govasli, Yuleima Diaz, Pål Puntervoll
    Vaccine.2019; 37(43): 6405.     CrossRef
  • Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications
    Alexandra N. Tsoras, Julie A. Champion
    Annual Review of Chemical and Biomolecular Engineering.2019; 10(1): 337.     CrossRef
  • Capsid containing virus like particle vaccine against Zika virus made from a stable cell line
    Himanshu Garg, Tugba Mehmetoglu-Gurbuz, Gregory M. Ruddy, Anjali Joshi
    Vaccine.2019; 37(48): 7123.     CrossRef
  • Incorporation of CD40 ligand enhances the immunogenicity of tumor‑associated calcium signal transducer 2 virus‑like particles against lung cancer
    Wang Xi, Dong Ke, Long Min, Wang Lin, Zuo Jiahui, Lin Fang, Gao Zhaowei, Zhang Zhe, Chen Xi, Zhang Huizhong
    International Journal of Molecular Medicine.2018;[Epub]     CrossRef
  • Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles
    Young-Seok Kim, Ahyun Son, Jihoon Kim, Soon Bin Kwon, Myung Hee Kim, Paul Kim, Jieun Kim, Young Ho Byun, Jemin Sung, Jinhee Lee, Ji Eun Yu, Chan Park, Yeon-Sook Kim, Nam-Hyuk Cho, Jun Chang, Baik L. Seong
    Frontiers in Immunology.2018;[Epub]     CrossRef
  • Nanoparticle vaccines against viral infections
    Fernando B. Sulczewski, Raquel B. Liszbinski, Pedro R. T. Romão, Luiz Carlos Rodrigues Junior
    Archives of Virology.2018; 163(9): 2313.     CrossRef
  • Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71
    Xi Wang, Ke Dong, Min Long, Fang Lin, Zhaowei Gao, Lin Wang, Zhe Zhang, Xi Chen, Ying Dai, Huiping Wang, Huizhong Zhang
    Archives of Virology.2018; 163(7): 1851.     CrossRef
  • Questions of bioethics and biosafety in the problem of biotechnology and use of vaccine for prevention of human infectious diseases
    V. Zadorozhna, N. Vynnyk
    Bulletin "Veterinary biotechnology".2018; 32(1): 459.     CrossRef
  • MultiBac: from protein complex structures to synthetic viral nanosystems
    Martin Pelosse, Hannah Crocker, Barbara Gorda, Paul Lemaire, Jens Rauch, Imre Berger
    BMC Biology.2017;[Epub]     CrossRef
  • Green Tea Catechin-Inactivated Viral Vaccine Platform
    Yun H. Lee, Yo H. Jang, Young H. Byun, Yucheol Cheong, Paul Kim, Young J. Lee, Yoon J. Lee, Je M. Sung, Ahyun Son, Hye M. Lee, Jinhee Lee, Seung W. Yang, Jae-Min Song, Baik L. Seong
    Frontiers in Microbiology.2017;[Epub]     CrossRef
  • Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus
    Himanshu Garg, Melina Sedano, Gabrielle Plata, Erin B. Punke, Anjali Joshi, Michael S. Diamond
    Journal of Virology.2017;[Epub]     CrossRef

Journal of Microbiology : Journal of Microbiology
TOP